Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
CompletedPhase 4NCT00139776
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
Study details
- Official title
- Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of "Continuous Use" Of Celecoxib Vs. The "Usual Use" Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-inflammatory Medication for Control Of Their Pain
- Conditions
- Interventions
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Organization
- Pfizer
- Start date
- 2005-07
- Primary completion
- 2008-02
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Belgium, Brazil, Canada, Chile, Colombia, France, United Kingdom, United States
- Total sites listed
- 124
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Subject has been diagnosed, according to American College of Rheumatology guidelines, with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory drugs (NSAIDs) to control their osteoarthritis pain and have access to a touch-tone telephone. Exclusion Criteria: * Subject has had surgery on index joint. * Subject has history of rheumatoid arthritis or fibromyalgia syndrome. * Subject has active gastrointestinal or cardiovascular disease.
Canadian sites (21)
| Facility | City | Province |
|---|---|---|
| Pfizer Investigational Site | Calgary | Alberta |
| Pfizer Investigational Site | Vancouver | British Columbia |
| Pfizer Investigational Site | St. John's | Newfoundland and Labrador |
| Pfizer Investigational Site | St. John's | Newfoundland and Labrador |
| Pfizer Investigational Site | St. John's | Newfoundland and Labrador |
| Pfizer Investigational Site | Corunna | Ontario |
| Pfizer Investigational Site | Hamilton | Ontario |
| Pfizer Investigational Site | London | Ontario |
| Pfizer Investigational Site | Newmarket | Ontario |
| Pfizer Investigational Site | North York | Ontario |
| Pfizer Investigational Site | Sarnia | Ontario |
| Pfizer Investigational Site | Toronto | Ontario |
| Pfizer Investigational Site | Windsor | Ontario |
| Pfizer Investigational Site | Charlottetown | Prince Edward Island |
| Pfizer Investigational Site | Montague | Prince Edward Island |
| Pfizer Investigational Site | Mirabel | Quebec |
| Pfizer Investigational Site | Montreal | Quebec |
| Pfizer Investigational Site | Rimouski | Quebec |
| Pfizer Investigational Site | Sherbrooke | Quebec |
| Pfizer Investigational Site | Ste-Foy | Quebec |
| Pfizer Investigational Site | Saskatoon | Saskatchewan |
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00139776